|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
|
Jun 2019
|
The Lancet Haematology
|
myelodysplastic syndromes (MDS)
|
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
|
Jun 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
|
Jun 2019
|
Current Hematologic Malignancy Report
|
myelodysplastic syndromes (MDS)
|
|
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
|
Jun 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Jul 2019
|
Surgical Pathology Clinic
|
myelodysplastic syndromes (MDS)
|
|
Management of aplastic anemia after failure of frontline immunosuppression
|
Jul 2019
|
Expert Review of Hematology
|
aplastic anemia
|
|
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
|
Sep 2019
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research
|
myelodysplastic syndromes (MDS)
|
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|
Sep 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
|
Sep 2019
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
